Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4369
Source ID: NCT00425919
Associated Drug: Ppm-204
Title: Study Evaluating PPM-204 In Subjects With Type 2 Diabetes
Acronym:
Status: TERMINATED
Study Results: NO
Results:
Conditions: Diabetes Mellitus
Interventions: DRUG: PPM-204
Outcome Measures: Primary: Fasting Plasma Glucose | Secondary: Mean changes of HbA1c, Fasting Insulin, HOMA-IR and QUICKI indices, Body weight, waist measurements, total cholesterol, LDL-C, HDL-C, total/HDL, apolipoprotein A-1 & B, triglycerides, free fatty acids, hs C-reactive protein, adiponectin, edema.
Sponsor/Collaborators: Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 500
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
Start Date: 2007-01
Completion Date: 2007-10
Results First Posted:
Last Update Posted: 2007-12-27
Locations: Artesia, California, 90701, United States|Los Angeles, California, 90057, United States|Chipley, Florida, 32428, United States|Destin, Florida, 32541, United States|Marianna, Florida, 32446, United States|West Palm Beach, Florida, 33401, United States|Omaha, Nebraska, 68131, United States|New York, New York, 10032, United States|Austin, Texas, 78705, United States|Richmond, Virginia, 23249, United States|Tacoma, Washington, 98405, United States|Buenos Aires, C1117ABH, Argentina|Corrientes, 3400, Argentina|La Plata, 1900, Argentina|Mar del Plata Pcia de Bs. As, 7600, Argentina|Ramos Mejia, Pcia de Bs., 1704, Argentina|Daws Park, South Australia, 5041, Australia|Keswick, South Australia, 5035, Australia|Box Hill, Victoria, 3128, Australia|Vila Clementino - Sao Paulo, 04020-060, Brazil|Edmonton, Alberta, T5G 3G6, Canada|Toronto, Ontario, M9W 4L6, Canada|Charlottetown, Prince Edward Island, C1E 1J7, Canada|Laval, Quebec, H7P 2P5, Canada|Saint-Janvier, Quebec, J7J 2K8, Canada|Beijing, 100730, China|Beijing, 100853, China|Krapinske Toplice, 49000, Croatia|Rijeka, 51000, Croatia|Zagreb, 10000, Croatia|Belgrade, 11000, Former Serbia and Montenegro|Athens, 115 21, Greece|Thessaloniki, 56429, Greece|Wanchai, Hong Kong|Bangalore, Karnataka, 560043, India|Cochin, Kerala, 682 026, India|Pune, Maharashtra, 411001, India|Chennai, Tamil nadu, 600 013, India|Vellore, Tamil Nadu, 632004, India|Catanzaro, 88100, Italy|Pisa, 56124, Italy|Aguascalientes, 20230, Mexico|Mexico D.F., 11650, Mexico|Mexico DF, 14000, Mexico|Miguel Hidalgo, 11550, Mexico|Monterrey N.L, 64410, Mexico|Tlapan, 14080, Mexico|Bucuresti, 10825, Romania|Bucuresti, 20475, Romania|Cluj-Napoca, 400006, Romania|Moscow, 117036, Russian Federation|Moscow, 117292, Russian Federation|Moscow, 123154, Russian Federation|Moscow, 125315, Russian Federation|St. Petersburg, 194044, Russian Federation|St. Petersburg, 194354, Russian Federation|Port Elizabeth, Eastern Cape, 6014, South Africa|Benoni, Gauteng, 1501, South Africa|Pretoria, Gauteng, 0002, South Africa|Pretoria, Gauteng, 39, South Africa|Temba, North West Province, 400, South Africa|Kharkiv, 61070, Ukraine|Kyiv, 02175, Ukraine|Poltava, 36024, Ukraine|Uzhgorod, 80312, Ukraine|Dundee, DD1 9SY, United Kingdom|Edinburgh, EH4 2XU, United Kingdom|Livingston, EH54 6PP, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00425919

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress